Quantcast

Industry news that matters to you.  Learn more

SensiDerm™ Animal Replacement Assays Selected By Cosmetics Europe

As of 13th March 2013, a ban was introduced in the European Union (EU) on animal testing of ingredients for cosmetics. The ban applies to all new cosmetics and their ingredients sold in the EU, regardless of where in the world testing on animals was carried out. Cosmetics Europe (formerly COLIPA), the European trade association for the cosmetic, toiletry and perfumery industry, is looking to introduce novel in-vitro assays for testing key sensitizers/allergens as a replacement for animal testing in cosmetics. This will also apply to other products including chemicals, pharmaceuticals, and household products. It means that any product within these categories will have to be tested for the presence of sensitizers.

Olink Bioscience Introduces Scalable Protein Biomarker Assays with Proseek Multiplex

Molecular tools specialist Olink today launched Proseek® Multiplex – a new generation of multiplexed protein biomarker immunoassays based on its proprietary Proximity Extension Assay (PEA) platform. Until now, it has been impossible to scale up conventional assays due to increased antibody cross-reactivity when large numbers of assays are run simultaneously. Now with the introduction of Proseek Multiplex, biomarker researchers can quantify 92 proteins in just one microliter sample without compromising data quality or performance.

“We are very proud at Olink to introduce a new and scalable era in immunoassays. Proseek has harnessed the tools that have fueled genomics for many years and put them to use in protein biomarker research. In a few years, we aim to offer the market’s most comprehensive portfolio of protein biomarker assays.” says Simon Fredriksson, CEO of Olink Bioscience.

First in the range is Proseek Multiplex Oncology I 96×96, a ready-to-use kit sold by Olink capable of analyzing 96 samples against a panel of analytes such as growth factors, inflammatory markers, soluble receptors, and cancer antigens. Further Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes will be introduced through 2013.

Minimal sample consumption makes Proseek Multiplex especially suitable for retroactively mining precious biobanked serum samples for novel multivariate biomarker signatures. It can also provide novel biomarker insights from sample types such as tissue lysates of needle biopsies and micro dialysis samples. Even in these small samples Proseek Multiplex can provide accurate quantification below pico-gram per milliliter levels.

Proseek is based on the proprietary PEA technology developed at Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

“This is major breakthrough. Suddenly the extremely sensitive, reproducible and reliable qPCR workflow since long established as the gold standard for DNA, mRNA, and microRNA analyses has become available also for the measurement of proteins. During our early access period we have established robust SOPs for the entire workflow from sample preparation to data analysis, and it will be a great pleasure supporting our clients with this exceedingly powerful new technology to advance their research.” says Professor Mikael Kubista, founder of TATAA Biocenter and renowned for his pioneering work in real time-PCR.

Source: Olink Bioscience

Agilent Technologies and Applied Proteomics Will Collaborate to Maximize Capabilities of Highly Multiplexed Protein Assays

Agilent Technologies Inc. (NYSE:A) and Applied Proteomics Inc. recently agreed to collaborate on highly multiplexed protein assays and workflow solutions for multiple reaction monitoring through mass spectrometry. Proteins perform many important cellular functions, are the targets of most drugs and therapies, and are often used as biomarkers for detecting and monitoring disease.

Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform

Biocartis has launched its revolutionary detection platform, Dynamic Multi-Analyte Technology (“DMAT”), a proteomic and nucleic acid platform that provides ultra-high quality data analysis even at higher multiplex formats. The platform launched well ahead of plan and Biocartis has flipped from a late-stage development company into a commercial business.

Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia

Aushon BioSystems has appointed AH diagnostics as its exclusive distributor in Scandinavia (Sweden, Norway, Finland, Denmark, Iceland), effective November 1, 2012. AH diagnostics will offer Aushon’s complete portfolio of Cira™ platform products including Cirascan™, Ciraplex™ and Cirasoft™ products for multiplex ELISAs.